A
Overview
Abcodia creates blood tests that help detect cancer early. Its main product, the ROCA Test, analyzes substances in blood (serum biomarkers) to estimate a woman's risk of having ovarian cancer, offering a non-invasive and affordable screening option. The company relies on a large serum biobank and a business model built around discovering and validating new biomarkers, then turning them into diagnostic tests sold to healthcare providers and partners. By focusing on non-invasive, early detection, Abcodia aims to improve treatment outcomes and survival rates for solid tumors overall.
Work here?Claim your company
Simplify's take
What believers are saying
- UCLH ROCA funding now extends through 2027, supporting continued clinical use.
- HSJ shortlisted the UCLH ROCA pathway in August 2026, validating clinical credibility.
- GENinCode signed Switzerland and Austria ROCA agreements in 2024, enabling European expansion.
What critics are saying
- GENinCode’s H1 2026 revenue fell to £1.1 million, pressuring Abcodia funding.
- ROCA adoption still depends on individual NHS trust budgets, slowing scale.
- If NHS expansion stalls and Thermo Fisher underdelivers, Abcodia becomes commercially stranded.
What makes Abcodia unique
- Abcodia owns ROCA, a NICE-endorsed ovarian-cancer surveillance algorithm within GENinCode.
- Its Manchester biobank and serum biomarker know-how support early-detection test development.
- UCLH became the first NHS trust using ROCA outside a trial setting.
Help us improve and share your feedback! Did you find this helpful?